Kevin R. Fox, MD, Director of the Rena Rowan Breast Center at Penn Medicine, offers a compelling assessment of the findings of breast cancer treatment studies presented at ASCO 2016. His discussion includes considerations of adjuvant anthrocycline and endocrine therapies and palbociclib in a variety of patients subsets, including lymph-node positive, estrogen and/or progesterone receptor positive and early stage breast cancers, focusing throughout on outcomes and adverse events.
Related Links
Published
February 7, 2017
Created by
BROADCASTMED